Skip to main content
Annals of Intensive Care
Fig. 3 | Annals of Intensive Care

Fig. 3

From: Early sevoflurane sedation in severe COVID-19-related lung injury patients. A pilot randomized controlled trial

Fig. 3

Shows the daily plasma values of inflammatory markers up to day 8 in patients subjected to continuous intravenous sedation or a 48 h intervention with sevoflurane. Interleukin 6 (IL-6, 3 A), angiopoietin-1 and − 2 (Ang-1 and Ang-2, 3 B and 3C), and soluble urokinase-type plasminogen activator receptor (suPAR, 3D) are illustrated. The dots represent mean values, error bars indicate the standard deviation (3A and 3B). Boxplots represent median and 25–75 percentiles, whiskers indicate 10–90 percentiles (3C and 3D)

Back to article page